Dexamethasone in hospitalized patients with Covid-19
RECOVERY Collaborative Group - New England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with diffuse lung
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …
Dexamethasone in hospitalized patients with Covid-19-preliminary report
Background: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage.
Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce …
Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce …
Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report
ABSTRACT Background Coronavirus disease 2019 (COVID-19) is associated with diffuse
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support
Background Dexamethasone decreases mortality in coronavirus disease 2019 (COVID-19)
patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill …
patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill …
[PDF][PDF] Short-term dexamethasone in Sars-CoV-2 patients
V Selvaraj, K Dapaah-Afriyie, A Finn, TP Flanigan - RI Med J, 2020 - rimed.org
ABSTRACT BACKGROUND: Dexamethasone, a synthetic glucocorticoid, has anti-
inflammatory and immunosuppressive properties. There is a hyperinflammatory response …
inflammatory and immunosuppressive properties. There is a hyperinflammatory response …
Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled …
J Villar, JM Añón, C Ferrando, G Aguilar, T Muñoz… - Trials, 2020 - Springer
Background There are no specific generally accepted therapies for the coronavirus disease
2019 (COVID-19). The full spectrum of COVID-19 ranges from asymptomatic disease to mild …
2019 (COVID-19). The full spectrum of COVID-19 ranges from asymptomatic disease to mild …
Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label …
M Taboada, N Rodríguez, PM Varela… - European …, 2022 - Eur Respiratory Soc
Background Low-dose dexamethasone demonstrated clinical improvement in patients with
coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the …
coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the …
Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX …
Importance Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019
(COVID-19) is associated with substantial mortality and use of health care resources …
(COVID-19) is associated with substantial mortality and use of health care resources …
Potential adverse effects of dexamethasone therapy on COVID-19 patients: review and recommendations
F Chen, L Hao, S Zhu, X Yang, W Shi, K Zheng… - Infectious diseases and …, 2021 - Springer
In the context of the coronavirus disease 2019 (COVID-19) pandemic, the global healthcare
community has raced to find effective therapeutic agents against severe acute respiratory …
community has raced to find effective therapeutic agents against severe acute respiratory …
High-versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomized open-label clinical trial
LP Maskin, I Bonelli, GL Olarte… - Journal of intensive …, 2022 - journals.sagepub.com
Objective To determine whether high-dose dexamethasone increases the number of
ventilator-free days (VFD) among patients with acute respiratory distress syndrome (ARDS) …
ventilator-free days (VFD) among patients with acute respiratory distress syndrome (ARDS) …